Share price close 16 Nov 2026
Quarterly or annual report filed
Quarterly or annual report filed
In one paragraph
Gilead Sciences reported revenue of $29.4 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 2.4% from fiscal 2024. Net income was $8.51 billion and diluted earnings per share $6.78.
In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $8.30 billion, up 6.8% from a year earlier.
Figures from Gilead Sciences's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026.
Against Health Care
Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.
Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.
| Product | Revenue | Share | Change |
|---|---|---|---|
| Biktarvy | $14.33B | 49% | +6.8% |
| Total Liver Disease | $3.22B | 11% | +6.5% |
| Descovy | $2.76B | 9.4% | +30.5% |
| Total Cell Therapy | $1.84B | 6.2% | −6.8% |
| Genvoya | $1.50B | 5.1% | −15.0% |
| Trodelvy | $1.40B | 4.7% | +6.2% |
| Sofosbuvir/Velpatasvir | $1.27B | 4.3% | −20.3% |
| Other lines (3) | $3.15B | 11% | — |
Gilead Sciences beside the other S&P 500 members in Biotechnology, by market value.
| Company | Market value | Day | 1 year | Revenue growth | Net margin | P/E |
|---|---|---|---|---|---|---|
| $210.2B | +0.1% | +36.2% | +6.5% | −12.5% | — | |
| $525.9B | +0.2% | +26.5% | +10.7% | 15.7% | 51.1 | |
| AmgenAMGN | $253.8B | −0.3% | +38.5% | +8.2% | 24.1% | 27.0 |
| $37.52B | +1.2% | +56.9% | +2.3% | 3.4% | 108.0 | |
| $24.67B | −0.6% | +11.7% | +24.9% | 6.7% | 61.2 | |
| — | −3.4% | +736% | — | — | — | |
| — | +0.4% | +40.2% | — | — | — |
Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.
Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.
| Revenue | FY 2024 | FY 2025 |
|---|---|---|
| Biktarvy | $13.42B | $14.33B+6.8% |
| Total Liver Disease | $3.02B | $3.22B+6.5% |
| Descovy | $2.11B | $2.76B+30.5% |
| Total Cell Therapy | — | $1.84B |
| Genvoya | $1.76B | $1.50B−15.0% |
| Trodelvy | $1.31B | $1.40B+6.2% |
| Sofosbuvir/Velpatasvir | $1.60B | $1.27B−20.3% |
| Odefsey | $1.29B | $1.17B−9.4% |
| Vemlidy | $959.0M | $1.07B+11.6% |
| Veklury | $1.80B | $911.0M−49.4% |
| Total revenue | $28.75B | $29.44B |
| Revenue | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| United States | $19.27B | $18.88B−2.0% | $19.44B+2.9% | $20.59B+5.9% | $20.88B+1.4% |
| Europe | $4.87B | $4.47B−8.3% | $4.31B−3.6% | $4.63B+7.5% | $5.06B+9.3% |
| Rest of World | $3.16B | $3.93B+24.1% | $3.37B−14.3% | $3.53B+4.8% | $3.50B−0.7% |
| Total revenue | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B |
Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.39B | $26.11B | $22.13B | $22.45B | $24.69B | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B |
| Revenue growth | −6.9% | −14.1% | −15.2% | +1.5% | +10.0% | +10.6% | −0.1% | −0.6% | +6.0% | +2.4% |
| Gross profit | $26.13B | $21.74B | $17.27B | $17.77B | $20.12B | $20.70B | $21.62B | $20.62B | $22.50B | $23.21B |
| Operating income | $17.63B | $14.12B | $8.20B | $4.29B | $4.07B | $9.92B | $7.33B | $7.61B | $1.66B | $10.02B |
| Net income | $13.50B | $4.63B | $5.46B | $5.39B | $123.0M | $6.22B | $4.59B | $5.67B | $480.0M | $8.51B |
| Diluted EPS | $9.94 | $3.51 | $4.17 | $4.22 | $0.10 | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Gross margin | 86.0% | 83.3% | 78.1% | 79.2% | 81.5% | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% |
| Operating margin | 58.0% | 54.1% | 37.1% | 19.1% | 16.5% | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% |
| Net margin | 44.4% | 17.7% | 24.7% | 24.0% | 0.5% | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $17.05B | $11.90B | $8.40B | $9.14B | $8.17B | $11.38B | $9.07B | $8.01B | $10.83B | $10.02B |
| Capital expenditure | $748.0M | $590.0M | $924.0M | $825.0M | $650.0M | $579.0M | $728.0M | $585.0M | $523.0M | $563.0M |
| Free cash flow | $16.30B | $11.31B | $7.48B | $8.32B | $7.52B | $10.80B | $8.34B | $7.42B | $10.30B | $9.46B |
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.23B | $7.59B | $17.94B | $11.63B | $6.00B | $5.34B | $5.41B | $6.08B | $9.99B | $7.56B |
| Total debt | $26.35B | $33.54B | $27.32B | $25.32B | $32.12B | $27.29B | $25.81B | $25.66B | $27.32B | $25.54B |
| Shareholders' equity | $18.89B | $20.44B | $21.39B | $22.52B | $18.20B | $21.07B | $21.24B | $22.83B | $19.33B | $22.70B |
| Diluted shares | 1.4B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B |
| Dividends per share | $1.84 | $2.08 | $2.28 | $2.52 | $2.72 | $2.84 | $2.92 | $3.00 | $3.08 | $3.16 |
The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.
| Period | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.57B | $6.67B | $7.08B | $7.77B | $7.92B | $6.96B | $7.80B | $8.30B |
| Revenue, year on year | +6.4% | −0.3% | +1.8% | +3.0% | +4.7% | +4.4% | +10.2% | +6.8% |
| Gross margin | 79.1% | 76.9% | 78.8% | 79.8% | 79.5% | 79.2% | 79.8% | 81.1% |
| Operating income | $2.45B | $2.24B | $2.47B | $3.33B | $1.98B | $2.59B | −$10.39B | $3.46B |
| Net income | $1.78B | $1.31B | $1.96B | $3.05B | $2.18B | $2.02B | −$10.50B | $2.43B |
| Diluted EPS | $1.39 | $1.04 | $1.56 | $2.43 | $1.74 | $1.61 | −$8.45 | $1.94 |
| Free cash flow | $2.83B | $1.65B | $720.0M | $3.96B | $3.12B | $2.43B | $3.43B | $4.80B |
The operating figures Gilead Sciences reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.
| KPI | Latest | Period | Change on a year | Recent periods |
|---|---|---|---|---|
| Product sales | $8.3B | quarter to 30 Sep 2026 | up 12.9% | |
| Biktarvy revenue | $4.1B | quarter to 30 Sep 2026 | up 10.1% | |
| Descovy revenue | $1.0B | quarter to 30 Sep 2026 | up 49.2% | |
| Trodelvy revenue | $506.0M | quarter to 30 Sep 2026 | up 41.7% | |
| Genvoya revenue | $339.0M | quarter to 30 Sep 2026 | down 10.1% | |
| Vemlidy revenue | $333.0M | quarter to 30 Sep 2026 | up 18.9% | |
| Yeztugo revenue | $305.0M | quarter to 30 Sep 2026 | up 682.1% | |
| Yescarta revenue | $294.0M | quarter to 30 Sep 2026 | down 15.8% | |
| Odefsey revenue | $286.0M | quarter to 30 Sep 2026 | up 3.2% | |
| Sofosbuvir/Velpatasvir revenue | $274.0M | quarter to 30 Sep 2026 | down 11.3% | |
| Livdelzi revenue | $203.0M | quarter to 30 Sep 2026 | up 93.3% | |
| Symtuza - Revenue share revenue | $132.0M | quarter to 30 Sep 2026 | up 6.5% | |
| AmBisome revenue | $99.0M | quarter to 30 Sep 2026 | down 19.5% | |
| Veklury revenue | $86.0M | quarter to 30 Sep 2026 | down 69.0% | |
| Tecartus revenue | $60.0M | quarter to 30 Sep 2026 | down 27.7% | |
| Royalty, contract and other revenues | $11.0M | quarter to 30 Sep 2026 | down 97.4% | |
| United States revenue | $6.4B | quarter to 30 Sep 2026 | up 20.5% | |
| Europe revenue | $1.1B | quarter to 30 Sep 2026 | down 31.5% | |
| Rest of World revenue | $872.0M | quarter to 30 Sep 2026 | down 6.5% |
Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.
The same figures as plain text and JSON.
$29.4 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.
$8.51 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).
$6.78 for fiscal year 2025 (the twelve months to 31 Dec 2025).
78.8% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.
34.0% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.
$9.46 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.
In fiscal 2025, by product: Biktarvy $14.33B (49%), Total Liver Disease $3.22B (11%), Descovy $2.76B (9.4%), Total Cell Therapy $1.84B (6.2%), out of $29.44B in all, as stated in its annual report.
In the terminal